BIONTECH SE - AMERICAN DEPOSITARY SHARES

113,13

22-ноября-24 15:44:58

15 мин. задержка

Акции

+4,90

+4,53%

Сегодняшний диапазон

107,41 - 114,32

ISIN

N/A

Источник

NASDAQ

BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024

22 апр 2024 05:45:00 Источник Nasdaq GlobeNewswire
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

07 апр 2024 13:00:00 Источник Nasdaq GlobeNewswire
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

20 мар 2024 05:15:00 Источник Nasdaq GlobeNewswire
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

20 мар 2024 05:00:00 Источник Nasdaq GlobeNewswire
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024

11 мар 2024 06:45:00 Источник Nasdaq GlobeNewswire
BioNTech Announces Planned Retirement of Sean Marett

07 мар 2024 05:45:00 Источник Nasdaq GlobeNewswire
BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024

06 мар 2024 05:45:00 Источник Nasdaq GlobeNewswire
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

08 фев 2024 04:45:00 Источник Nasdaq GlobeNewswire
BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305

31 янв 2024 05:45:00 Источник Nasdaq GlobeNewswire
BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer

22 янв 2024 05:45:00 Источник Nasdaq GlobeNewswire
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference

09 янв 2024 05:45:00 Источник Nasdaq GlobeNewswire
BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer

21 дек 2023 07:00:00 Источник Nasdaq GlobeNewswire
BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda

18 дек 2023 12:15:00 Источник Nasdaq GlobeNewswire
BioNTech to Inaugurate First African Site on December 18, 2023

12 дек 2023 05:45:00 Источник Nasdaq GlobeNewswire
BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update

06 ноя 2023 05:45:00 Источник Nasdaq GlobeNewswire
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19

26 окт 2023 05:45:00 Источник Nasdaq GlobeNewswire
BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023

23 окт 2023 10:30:00 Источник Nasdaq GlobeNewswire
BioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to Host Innovation Series Day on November 7, 2023

23 окт 2023 05:45:00 Источник Nasdaq GlobeNewswire
BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

19 окт 2023 05:45:00 Источник Nasdaq GlobeNewswire
BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023

16 окт 2023 02:30:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.